Grant: Discovery Grants Program - Individual
University of Victoria
$48,000.00
Defining New Biological and Chemical Targets With Diazirines
EF 2024-25
Résumé
Medicinal chemistry involves using molecules (drugs) to perturb biological systems. This mostly happens through formation of transient small-molecule-protein complexes, where a drug strongly and selectively binds to its protein target(s). The ability to predictably form association complexes between disease-relevant proteins and drug molecules underpins modern medicine, but identifying such complexes for the first time (i.e. discovering new protein binding pockets whose function can be regulated with drug-like small molecules or probes) has historically been done haphazardly, through target-identification campaigns with molecules of known phenotype or through high-throughput screens with pre-validated protein targets. Because of this, fewer than 500 of the proteins encoded by the 20,000 genes in our genome have approved drugs that selectively target them.1 Thousands of additional, medically relevant proteins cannot be controlled with existing small-molecule therapeutics.2 One of the foundational goals of chemical biology is to solve this limitation by identifying a small-molecule regulator for every member of the human proteome.2,3
To meet this grand challenge, our proposed research program will exploit diazirine-enabled complex molecules to search for protein binding partners at the same time as we exploit diazirine-enabled proteins to prospect for small molecule ligands. In a marked departure from established protocols, we will do so without any requirement for our molecules of interest to possess known phenotypic activity. Instead, we posit that every molecule possessing "drug-like" characteristics and a sufficient degree of molecular complexity will have a suite of proteins to which it binds most strongly. We likewise assert that the identification of small-molecule ligands for hypothesized protein pockets is a valuable undertaking that is likely to lead to new scientific understanding, even when that pocket does not have any known regulatory function. Of course, when new regulatory pockets are identified in disease-relevant proteins, these will have immediate utility for drug development.
Our research will thus lead directly to the annotation of new biological targets for medicinal chemistry, and will simultaneously deliver new lead compounds that bind to those targets-setting the stage for multiple future collaborative drug discovery projects.
This program represents a bold new direction for our group, yet builds upon expertise in organic synthesis, complex molecule characterization, target identification, chemical biology, and diazirine chemistry acquired by our team over the past 15 years. At the same time the research will allow us to develop new skills in proteomics, and in the site-specific incorporation of noncanonical amino acids. The program will provide a fertile training ground for highly qualified personnel, allowing my lab to build upon our considerable record of accomplishment mentoring and teaching successful scientists.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
RGPIN-2021-02560
Name nom
Wulff, Jeremy
Department département
Chemistry
Organization id
7
Institution établissement
University of Victoria
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2021
Award amount
48000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1504
Committee name en
Chemistry
Committee name fr
Chimie
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3703
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic syntheses
Research subject fr
Synthèses organiques
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Defining New Biological and Chemical Targets With Diazirines
Keywords
tandem reactions; multicomponent reactions; chemical biology; diazirines; target identification; noncanonical amino acid incorporation
Application summary
Medicinal chemistry involves using molecules (drugs) to perturb biological systems. This mostly happens through formation of transient small-molecule-protein complexes, where a drug strongly and selectively binds to its protein target(s). The ability to predictably form association complexes between disease-relevant proteins and drug molecules underpins modern medicine, but identifying such complexes for the first time (i.e. discovering new protein binding pockets whose function can be regulated with drug-like small molecules or probes) has historically been done haphazardly, through target-identification campaigns with molecules of known phenotype or through high-throughput screens with pre-validated protein targets. Because of this, fewer than 500 of the proteins encoded by the 20,000 genes in our genome have approved drugs that selectively target them.1 Thousands of additional, medically relevant proteins cannot be controlled with existing small-molecule therapeutics.2 One of the foundational goals of chemical biology is to solve this limitation by identifying a small-molecule regulator for every member of the human proteome.2,3
To meet this grand challenge, our proposed research program will exploit diazirine-enabled complex molecules to search for protein binding partners at the same time as we exploit diazirine-enabled proteins to prospect for small molecule ligands. In a marked departure from established protocols, we will do so without any requirement for our molecules of interest to possess known phenotypic activity. Instead, we posit that every molecule possessing "drug-like" characteristics and a sufficient degree of molecular complexity will have a suite of proteins to which it binds most strongly. We likewise assert that the identification of small-molecule ligands for hypothesized protein pockets is a valuable undertaking that is likely to lead to new scientific understanding, even when that pocket does not have any known regulatory function. Of course, when new regulatory pockets are identified in disease-relevant proteins, these will have immediate utility for drug development.
Our research will thus lead directly to the annotation of new biological targets for medicinal chemistry, and will simultaneously deliver new lead compounds that bind to those targets-setting the stage for multiple future collaborative drug discovery projects.
This program represents a bold new direction for our group, yet builds upon expertise in organic synthesis, complex molecule characterization, target identification, chemical biology, and diazirine chemistry acquired by our team over the past 15 years. At the same time the research will allow us to develop new skills in proteomics, and in the site-specific incorporation of noncanonical amino acids. The program will provide a fertile training ground for highly qualified personnel, allowing my lab to build upon our considerable record of accomplishment mentoring and teaching successful scientists.